TG Therapeutics
TGTX
236 hedge funds and large institutions have $763M invested in TG Therapeutics in 2023 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 100 increasing their positions, 51 reducing their positions, and 54 closing their positions.
96% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 51
5% more call options, than puts
Call options by funds: $25.3M | Put options by funds: $24M
0.9% more ownership
Funds ownership: 59.17% → 60.06% (+0.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 244 → 236 (-8)
11% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 54
65% less capital invested
Capital invested by funds: $2.19B → $763M (-$1.43B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$58.4M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$50.5M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$34.1M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$26.3M |
| 5 |
6CM
683 Capital Management
New York
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$230M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$71.8M |
| 3 |
Holocene Advisors
New York
|
-$40.4M |
| 4 |
Alkeon Capital Management
New York
|
-$38.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$20.1M |
TGTX Hedge Fund Activity: Q3 2023 in Review
236 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2023, worth a combined $763M — down 65% from $2.19B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of TGTX and 48 opened new positions — a net loss of 6 holders — while 51 trimmed existing stakes and 100 added.
The largest buyer was State Street, adding an estimated $58.4M. The largest seller was Darwin Global Management, exiting entirely with an estimated $230M sold.
- 236 institutional investors held TG Therapeutics (TGTX) as of Q3 2023, down from 244 in Q2 2023.
- Funds reported $763M of TG Therapeutics stock for Q3 2023, down 65% quarter-over-quarter.
- 48 funds opened new TG Therapeutics positions in Q3 2023 and 54 closed out, a net change of -6 holders.
- The largest TG Therapeutics buyer in Q3 2023 was State Street, an estimated $58.4M added.
- The largest TG Therapeutics seller in Q3 2023 was Darwin Global Management, an estimated $230M sold.
Based on aggregated 13F filings for Q3 2023.